Pharmaceutical services company i3 has entered the next phase of its global expansion which includes organic and acquired growth in India, Latin America and Europe.

Coupled with acquisitions in Canada and Asia Pacific that i3 made earlier this year, the additions will help i3’s pharmaceutical clients bring high-quality, well-tested drugs to market faster and cheaper.

i3’s Latin American expansion is due to its acquisition of one of the region’s largest privately held contract research organizations, which has operations in Argentina, Brazil, Costa Rica, Mexico, Peru and Uruguay. Its expansion in India includes the opening of a full service office in Delhi, which will provide clinical research and data services for India-specific and global drug trials. New offices in Poland and expanded offices in France and the United Kingdom will boost the company’s European presence.

 …